Similar articles for PMID: 24344151

Year	Number of Results
2006	2
2007	2
2008	3
2009	4
2010	5
2011	12
2012	22
2013	33
2014	9
2015	7
2016	4
2017	4
2018	4
2019	3
2020	6
2021	1
2022	1
2024	0

1

Treating Clostridium difficile infection.

Shafran DM, Shafran SD. Shafran DM, et al. CMAJ. 2014 Apr 15;186(7):531. doi: 10.1503/cmaj.131315. Epub 2013 Dec 16. CMAJ. 2014. PMID: 24344151 Free PMC article. Review. No abstract available.

2

Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.

Johnson S, Gerding DN, Louie TJ, Ruiz NM, Gorbach SL. Johnson S, et al. Antimicrob Agents Chemother. 2012 Aug;56(8):4043-5. doi: 10.1128/AAC.00605-12. Epub 2012 May 21. Antimicrob Agents Chemother. 2012. PMID: 22615287 Free PMC article. No abstract available.

3

[Clostridium difficile infections - still a major challenge].

Strauss R, Neurath MF. Strauss R, et al. MMW Fortschr Med. 2013 Apr 18;155(7):57-9. doi: 10.1007/s15006-013-0436-9. MMW Fortschr Med. 2013. PMID: 23668179 German. No abstract available.

4

Fecal transplantation therapy for Clostridium difficile-associated pouchitis.

Patel LN, Schairer J, Shen B. Patel LN, et al. Int J Colorectal Dis. 2014 Feb;29(2):263-4. doi: 10.1007/s00384-013-1771-0. Epub 2013 Oct 17. Int J Colorectal Dis. 2014. PMID: 24132529 No abstract available.

5

Fidaxomicin: a review of its use in patients with Clostridium difficile infection.

Scott LJ. Scott LJ. Drugs. 2013 Oct;73(15):1733-47. doi: 10.1007/s40265-013-0134-z. Drugs. 2013. PMID: 24136090 Review.

6

Fidaxomicin: in Clostridium difficile infection.

Duggan ST. Duggan ST. Drugs. 2011 Dec 24;71(18):2445-56. doi: 10.2165/11208220-000000000-00000. Drugs. 2011. PMID: 22141387

7

Clostridium difficile infection and antibiotic-associated diarrhoea.

Mullish BH, Williams HR. Mullish BH, et al. Clin Med (Lond). 2018 Jun;18(3):237-241. doi: 10.7861/clinmedicine.18-3-237. Clin Med (Lond). 2018. PMID: 29858434 Free PMC article. Review.

8

Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea.

Clutter DS, Dubrovskaya Y, Merl MY, Teperman L, Press R, Safdar A. Clutter DS, et al. Antimicrob Agents Chemother. 2013 Sep;57(9):4501-5. doi: 10.1128/AAC.01120-13. Epub 2013 Jul 8. Antimicrob Agents Chemother. 2013. PMID: 23836168 Free PMC article.

9

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.

Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. Goldstein EJ, et al. Antimicrob Agents Chemother. 2011 Nov;55(11):5194-9. doi: 10.1128/AAC.00625-11. Epub 2011 Aug 15. Antimicrob Agents Chemother. 2011. PMID: 21844318 Free PMC article. Clinical Trial.

10

Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.

Eyre DW, Babakhani F, Griffiths D, Seddon J, Del Ojo Elias C, Gorbach SL, Peto TE, Crook DW, Walker AS. Eyre DW, et al. J Infect Dis. 2014 May 1;209(9):1446-51. doi: 10.1093/infdis/jit598. Epub 2013 Nov 11. J Infect Dis. 2014. PMID: 24218500 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

112 results

Results by year